Bio

Background and Format: EP Vantage was launched in 2007 by EvaluatePharma, a source for pharma and biotech analysis. Their unique access to EvaluatePharma Alpha’s Calendar of Events allows coverage of potential market catalysts weeks and even months ahead of other industry sources while Alpha’s NPV (Net Present Value) Analyzer aims to put events into context, quantifying the impact on product and company valuation. EP Vantage aims to provide timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. Audience and Readership: EP Vantage is targeted at people working in the global pharmaceutical industry. Deadline: Ongoing (website). Monthly Unique Users: This figure is not disclosed by the publisher. Awards: 2011 - European Mediscience Awards, Commentator of the Year (Winner) Gorkana Alert: Wednesday 10 June 2015 Madeleine Armstrong is now Reporter at EP Vantage. Previously Deputy Editor at Clinica, she will be covering the pharmaceuticals and medical technology sectors. Madeleine can be reached at madeleinea@epvantage.com and can be also found tweeting at www.twitter.com/medtech_ma   Gorkana alert: Wednesday 30th April 2008 EP Vantage, the comment and analysis service for the pharma and biotech industries, has launched its new website www.epvantage.com. Targeted at the financial community and senior pharmaceutical executives, EP Vantage offers in-depth financial commentary and analysis on a wide range of issues including patent litigation, M&A, licensing and product approvals. As part of the launch of epvantage.com new users are eligible for a limited free trial. EP Vantage, part of EvaluatePharma, is edited by Lisa Urquhart, former Biotechnology Correspondent at the Financial Times. Lisa can be reached on +44 (0)20 7539 1819 and lisau@epvantage.com Gorkana Alert: Monday 13th August 2007 Lisa Urquhart, formerly Biotechnology Correspondent at the Financial Times, is Editor of EP Vantage, a new online financial news and analysis service for the pharmaceutical and biotechnology sectors. Lisa is joined by Amy Brown, most recently a Reporter at Thomson Financial News, covering biotechnology and pharmaceutical. Amy starts today as Senior Reporter. The editorial team also includes Christian Glennie, Senior Editorial Analyst from EvaluatePharma, who has over six years experience as a pharmaceutical analyst. Set to launch in autumn 2007, EP Vantage will offer in-depth financial commentary and analysis of a wide range of industry issues and trends. It will be targeted at senior pharmaceutical executives, hedge fund managers, investment banks, advisers and public and private company investors.   The EP Vantage editorial team can be reached on the following numbers and email addresses: Lisa Urquhart, Editor, lisau@epvantage.com and +44 (0)20 7539 1819 Amy Brown, amyb@epvantage.com and +44 (0)20 7539 1808 Christian Glennie,